{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:58:28Z","timestamp":1770134308352,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1245\/s10434-018-6389-6","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T19:29:20Z","timestamp":1519414160000},"page":"1418-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Predicting Survival and Response to Treatment in Gastroesophageal Neuroendocrine Tumors: An Analysis of the National Cancer Database"],"prefix":"10.1245","volume":"25","author":[{"given":"Katherine D.","family":"Gray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen D.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suraj","family":"Panjwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adham","family":"Elmously","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheguevara","family":"Afaneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Thomas J.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasa","family":"Zarnegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"issue":"1","key":"6389_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3748\/wjg.15.1","volume":"15","author":"MD Burkitt","year":"2009","unstructured":"Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2009;15(1):1\u201316.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"6389_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-F","volume":"104","author":"G Rindi","year":"1993","unstructured":"Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994\u20131006.","journal-title":"Gastroenterology"},{"issue":"9","key":"6389_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/j.1365-2036.2006.03130.x","volume":"24","author":"MD Burkitt","year":"2006","unstructured":"Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther. 2006;24(9):1305\u20131320. \n                    https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03130.x\n                    \n                  .","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"6389_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.sla.0000167862.52309.7d","volume":"242","author":"K Borch","year":"2005","unstructured":"Borch K, Ahr\u00e9n B, Ahlman H, Falkmer S, Gran\u00e9rus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64\u201373.","journal-title":"Ann Surg"},{"issue":"1","key":"6389_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1590\/s0004-2803.2017v54n1-01","volume":"54","author":"F Tustumi","year":"2017","unstructured":"Tustumi F, Takeda FR, Uema RH, Pereira GLS, Sallum RAA, Cecconello I. Primary neuroendocrine neoplasm of the esophagus\u2013Report of 14 cases from a single institute and review of the literature. Arq Gastroenterol. 2017;54(1):4\u201310. \n                    https:\/\/doi.org\/10.1590\/s0004-2803.2017v54n1-01\n                    \n                  .","journal-title":"Arq Gastroenterol"},{"issue":"6","key":"6389_CR6","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.21037\/jtd.2016.04.21","volume":"8","author":"H-Y Deng","year":"2016","unstructured":"Deng H-Y, Ni P-Z, Wang Y-C, Wang W-P, Chen L-Q. Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis. 2016;8(6):1250\u20131256. \n                    https:\/\/doi.org\/10.21037\/jtd.2016.04.21\n                    \n                  .","journal-title":"J Thorac Dis"},{"key":"6389_CR7","doi-asserted-by":"crossref","unstructured":"Harmse JL, Carey FA, Baird AR, et al. Merkel cells in the human oesophagus. J Pathol. 1999;189(2):176\u2013179. https:\/\/doi.org\/10.1002\/(SICI)1096-9896(199910)189:2<176::AID-PATH416>3.0.CO;2-U.","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<176::AID-PATH416>3.0.CO;2-U"},{"issue":"3","key":"6389_CR8","doi-asserted-by":"publisher","first-page":"e0173501","DOI":"10.1371\/journal.pone.0173501","volume":"12","author":"A Egashira","year":"2017","unstructured":"Egashira A, Morita M, Kumagai R, et al. Neuroendocrine carcinoma of the esophagus: clinicopathological and immunohistochemical features of 14 cases. PLoS ONE. 2017;12(3):e0173501. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0173501\n                    \n                  .","journal-title":"PLoS ONE"},{"issue":"18","key":"6389_CR9","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u20133072. \n                    https:\/\/doi.org\/10.1200\/jco.2007.15.4377\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"8","key":"6389_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","volume":"81","author":"E Mitry","year":"1999","unstructured":"Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81(8):1351\u20131355. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6690325\n                    \n                  .","journal-title":"Br J Cancer"},{"key":"6389_CR11","doi-asserted-by":"crossref","unstructured":"Moertel CG, Kvols LK, O\u2019Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991. Available at: \n                    http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/1097-0142(19910715)68:2%3C227:AID-CNCR2820680202%3E3.0.CO;2-I\/abstract\n                    \n                  .","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I"},{"issue":"1","key":"6389_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","volume":"13","author":"MH Kulke","year":"2015","unstructured":"Kulke MH, Shah MH, Benson AB, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13(1):78\u2013108.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"6389_CR13","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ejso.2016.08.004","volume":"42","author":"JW Xie","year":"2016","unstructured":"Xie JW, Sun YQ, Feng CY, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42(10):1464\u20131470. \n                    https:\/\/doi.org\/10.1016\/j.ejso.2016.08.004\n                    \n                  .","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"6389_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152\u2013160. \n                    https:\/\/doi.org\/10.1093\/annonc\/mds276\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"4","key":"6389_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/PAS.0b013e31826d2639","volume":"37","author":"Q Huang","year":"2013","unstructured":"Huang Q, Wu H, Nie L, et al. Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol. 2013;37(4):467\u2013483. \n                    https:\/\/doi.org\/10.1097\/pas.0b013e31826d2639\n                    \n                  .","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"6389_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/annonc\/mdm476","volume":"19","author":"GY Ku","year":"2008","unstructured":"Ku GY, Minsky BD, Rusch VW, Bains M, Kelsen DP, Ilson DH. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan\u2013Kettering experience. Ann Oncol. 2008;19(3):533\u2013537. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdm476\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"6","key":"6389_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","volume":"39","author":"JR Strosberg","year":"2010","unstructured":"Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799\u2013800. \n                    https:\/\/doi.org\/10.1097\/mpa.0b013e3181ebb56f\n                    \n                  .","journal-title":"Pancreas"},{"issue":"6","key":"6389_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1530\/ERC-12-0002","volume":"19","author":"O Hentic","year":"2012","unstructured":"Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19(6):751\u2013757. \n                    https:\/\/doi.org\/10.1530\/erc-12-0002\n                    \n                  .","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"6389_CR19","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","volume":"13","author":"S Ekeblad","year":"2007","unstructured":"Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986\u20132991. \n                    https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-2053\n                    \n                  .","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-018-6389-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6389-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6389-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T19:45:57Z","timestamp":1581968757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-018-6389-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["6389"],"URL":"https:\/\/doi.org\/10.1245\/s10434-018-6389-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]},"assertion":[{"value":"4 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}